News | October 08, 2024
AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy
CSPC will receive an upfront payment of $100 million from AstraZeneca
CSPC will receive an upfront payment of $100 million from AstraZeneca
The acquisition will strengthen the overall company’s position as leading global CRO services partner
he company will focus on production of any pharmaceutical and biotechnological products
Poor oral health (periodontal disease) impacts nearly 51% of Indians
USFDA completes PAI of Lupin’s biotech facility in Pune
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Cetirizine is used for relief of symptoms of hay fever and other allergic conditions
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Subscribe To Our Newsletter & Stay Updated
